



Investments will 'shine out'

Deva Holding Chairman of the Executive Board and CEO Philipp Haas, having stated that they planned the investments in 2013 based on the fact that, in Turkey, pharmaceutical import is more than 10 times higher the pharmaceutical export, said that pharmaceutical import increased almost by seven times between the years of 2000 and 2012. Having indicated that DEVA was established 55 years ago by a group of people constituted by 26 people expressed that "Now we also want to shine out. In 2013 when we are celebrating our 55th year, our aim is to advance from the fourth rank to the top ranks". Mr. Haas, indicating that Turkey ranks the 16th on the world in respect of market size of pharmaceutical sector, said that "We believe that Turkey can be a global actor in pharmaceutical industry only through domestic manufacture of majority of products imported today. This is our dream for the following years. As DEVA Holding, we hold our end of the bargain to lead this movement". Haas, who made a speech in the meeting held for the 55th year of the holding, expressed that DEVA Holding ended the year of 2012 with turnover of 419.5 million dollars and that the net profit is 34.2 million liras.

MAIN POINT IS R&D

Mr. Haas, stating that they carry out their R&D operations in their modern facilities equipped with state-of-the-art technology, said that "R&D constitutes the basic point for Turkey to have the capability for self-sufficient drug production and even for export. We spared approximately 6 percent of our turnover for R&D in 2012. Also in 2013, we will continue with our investments in this area for manufacture and release of effective and safe drugs of international standards in our country

Oncological production center has been established

Having indicated that they have established the largest oncological production center of the world said that "Our production is of the same quality as that of Europe and USA and standards have become equal. Seven-year regulatory process at minimum is required for our export products. There must be 'equivalence' for inspection of export and import. In oncological drug production given great prominence on the world, we built a production facility superior than the world standards. By working in full capacity, we want to

prevent unnecessary expenditure made for pharmaceutical import'.